Hearts & Minds Blog

Esperion Investor Day: Lighting the Way for Phase 2b Results

Tim Mayleben

President and Chief Executive Officer

On July 29th, Esperion held its inaugural investor day in New York City, with a tightly-packed agenda for the half-day… more

Reflections One Year Post-IPO

Tim Mayleben

President and Chief Executive Officer

One year ago today the “new” Esperion re-entered the public markets with an initial public offering that raised $80 million… more

Posted In: Company News

NLA 2014 Scientific Sessions: Placing the Focus on Statin Intolerance

Roger Newton, PhD, FAHA

Executive Chairman and Chief Scientific Officer

Marianne Andreach

Senior Vice President, Strategic Marketing and Product Planning

As members of the Esperion team developing ETC-1002—a unique, first-in-class, orally available, once-daily small molecule designed to lower low density… more

Working to Impact the Lives of Millions of Statin Intolerant Patients

Tim Mayleben

President and Chief Executive Officer

I re-joined Roger at Esperion almost a year ago to help people who are at risk for debilitating and life-threatening… more

Posted In: Company News

Getting the Band Back Together

Roger Newton, PhD, FAHA

Executive Chairman and Chief Scientific Officer

Late last year, one of the country’s most brilliant scientists called me and asked if I wanted to help him… more